The Effects of Glucose Control and Weight Loss Between Beinaglutide and Dulaglutide in Type 2 Diabetes With Overweight or Obesity.

Inclusion Criteria: 1. Age between 18 to 70 years old from all sex; 2. Diagnosed with type 2 diabetes and HbA1c between 7% to 10%; 3. BMI from 24 to 35kg/m² or waistline longger than 90cm（male）/85cm（female）; 4. Volunteer to participate in the study with informed consent; Exclusion Criteria: 1. Type 1 diabetes or other specific types of diabetes; 2. Taking drugs of GLP-1 receptor agonist、TZDs and SGLT2 inhibitor within 3 months of screening; 3. Taking insulin or insulin analogues more than 7 days within 3 months of screening; 4. Pregnancy, breastfeeding or planned pregnancy; 5. History of acute or chronic pancreatitis; 6. Taking glucocorticoids(oral or intravenous) continuously more than 7 days within 6 months of screening; 7. Alanine aminotransferase or aspartate transaminase more than 3 times of the normal upper limit, total bilirubin more than 2 times of the normal upper limit; 8. renal impairment (estimated glomerular filtration rate\<60mL/min per 1.73 m²); 9. History of gastrointestinal disease; 10. History of malignant tumor within 5 years of screening; 11. History of organ transplantation or AIDS; 12. History of glaucoma; 13. History of hyperthyroidism or hypothyroidism; 14. History of medullary thyroid carcinoma or multiple endocrine neoplasia II; 15. History of abnormal of Calcitonin or thyroid tumor; 16. History of alcohol abuse; 17. Recruited by other clinical trials within 3 months of screening; 18. Taking drugs of weight loss within 3 months of screening; 19. History of bariatric surgery; 20. History of mental disorders; 21. History of rheumatic diseases or autoimmune diseases; 22. Allergic to beinaglutide or dulaglutide; 23. Participants who estimated would not be suitable for the study by the investigators.